SVC-isolation in Redo-AF Ablation With Isolated PV (SVC-RESCUE-AF)

Superior Vena Cava Isolation With Radiofrequency Ablation in Patients With Recurrent Paroxysmal Atrial Fibrillation and Durably Isolated Pulmonary Veins: A Multicenter Study

Atrial fibrillation is the most common arrhythmia in the population and is often caused by arrhythmogenic foci located in the pulmonary veins. For this reason, the first attempt in atrial fibrillation catheter ablation procedures is to isolate these structures (the procedure is called indeed "pulmonary vein isolation"), which results in abolishment of arrhythmia recurrence in up to 85% of patients at short and mid-term follow-up. However, a subset of patients experience an atrial tachyarrhytmia recurrence and a second catheter ablation procedure has to be performed. If pulmary vein isolation is proven to be durable, other arrhythmogenic foci could be implicated in arrhythmia recurrence. Among extra-pulmonary vein foci, superior vena cava has been described as the most frequently involved in atrial fibrillation initiation. Therefore, its ablation could result in improved freedom from atrial fibrillation episodes during follow-up. In the present study, we sought to evaluate the safety and effectiveness of empirical superior vena cava isolation in terms of arrhythmia-free survival in patients with paroxysmal atrial fibrillation recurrence despite durable pulmonary vein isolation.

Study Overview

• Status: Not yet recruiting
• Conditions: Paroxysmal AF
• Intervention / Treatment: Procedure: Empirical superior vena cava isolation; Procedure: Ablation without empirical superior vena cava isolation

Detailed Description

Atrial fibrillation (AF) is the most frequent arrhythmia in the general population (1), with an expected doubling in prevalence within 2060 (2). Since the late 1990s (3), pulmonary vein isolation (PVI) has become a cornerstone in drug refractory AF treatment, and more recently has emerged a first line therapy in paroxysmal AF patients (4) due to its proven superiority to antiarrhythmic drugs in achieving arrhythmia-free survival (5).

PVI is a safe and effective procedure in the vast majority of patients with paroxysmal AF, with high AF-free survival at mid- and long-term follow-up. In case of AF recurrence, repeat ablation of pulmonary vein reconnections demonstrated superior outcomes compared to the use of anti-arrhythmic drugs in both paroxysmal and persistent AF (6). Nevertheless, a subset of patients with AF recurrence results to be "PVI non-responder", with arrhythmia recurrence despite durable ablation results (7). How to manage these patients is still a matter of debate, with different additional lesion sets proposed so far (8).

Non-PVI triggers have been implicated in AF initiation, with superior vena cava (SVC) being the most common of them (9,10). Empirical SVC isolation has been attempted in some observational as well as randomized study (11-14), but definitive conclusion could not be drawn due to lack of statistical power as well as variable eligibility criteria (first vs repeat procedure, paroxysmal vs persistent AF) and ablation sets (15).

In the present study, we sought to evaluate the safety and effectiveness of empirical SVC isolation in terms of arrhythmia-free survival in patients with paroxysmal AF recurrence despite durable PVI.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Antonio Berruezo, MD, PhD; Phone Number: + 34 93 290 62 51; Email: antonio.berruezo@quironsalud.es
• Study Contact Backup: Name: Diego Penela, MD, PhD; Email: diego.penelamaceda@humanitas.com

Study Locations

• Spain
  • Barcelona, Spain, 08034
    • Heart Institute, Teknon Medical Centre
    • Contact: Antonio Berruezo, MD, PhD; Phone Number: + 34 93 290 62 51; Email: antonio.berruezo@quironsalud.es

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age > 18 years.
2. Confirmed diagnosis of recurrent paroxysmal AF
3. Previous transcatheter PVI-only procedure for AF.
4. Evidence of persistently isolated pulmonary veins at repeat procedure.
5. Signed informed consent.

Exclusion Criteria:

• Age < 18 years.
• Pregnancy.
• Concomitant investigation treatments.
• Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.
• Lesions other than PVI performed during first procedure
• Persistent AF at recurrence.
• Evidence of pulmonary vein reconnection at repeat procedure.
• Any additional lesion performed beyond SVC isolation during repeat procedure (in the empirical SVC isolation group only).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: SVC isolation group; Empirical superior vena cava isolation	Procedure: Empirical superior vena cava isolation; Empirical superior vena cava isolation with radiofrequency ablation
Sham Comparator: Control arm; No empirical superior vena cava isolation	Procedure: Ablation without empirical superior vena cava isolation; No ablation or ablation of other arrhythmic foci wuthout empirical superior vena cava isolation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Arrhythmia-free survival	Occurence of any sustained atrial arrhythmia (AF, atrial flutter or any atrial tachycardia) lasting ≥ 30 s, after a 2-month blanking period	12 months follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Procedure-related complications	Any procedure complication	12 months follow-up

Collaborators and Investigators

• Sponsor: Centro Medico Teknon
• Investigators: Principal Investigator: Antonio Berruezo, MD, PhD, Teknon Medical Centre

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2025
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027

Study Registration Dates

• First Submitted: August 2, 2025
• First Submitted That Met QC Criteria: August 2, 2025
• First Posted (Actual): August 8, 2025

Study Record Updates

• Last Update Posted (Actual): August 8, 2025
• Last Update Submitted That Met QC Criteria: August 2, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Atrial fibrillation; Recurrence; Paroxysmal; Superior Vena Cava Isolation
• Other Study ID Numbers: SVC-RESCUE-AF (Other Identifier: Teknon Medical Centre)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No